About Us

Paul Thomson and Madhu Venkat, the founders of LevoPharm, collectively contribute over 50 years of healthcare experience.

Paul Thomson

Paul is a registered Pharmacist in Ontario, Alberta, and British Columbia, with 40 years of experience in Pharmacy Operational and Business Development. Throughout his career, he has held several senior positions within large Pharmacy chains, overseeing budgets of up to $600m in sales. By leveraging his expertise, Paul has successfully increased revenues by up to 27% through effective mergers and acquisitions.

Paul’s contributions to the pharmaceutical industry extend beyond financial success. He has implemented numerous best practices for pharmaceutical care across multiple Pharmacy markets in Canada, earning him a reputation for excellence. His entrepreneurial mindset, emphasis on teamwork, and collaborative approach to Pharmacy management have consistently provided him with a competitive advantage in various markets.

Over the years, Paul has also been a proud owner of his own Pharmacies. During this time, he emphasized a highly professional and service-driven approach, fostering interactive relationships with patients based on care and compassion.

In addition to his extensive experience in Pharmacy operations, Paul has developed a wealth of expertise in specialty Pharmacy, including addictions treatment and Long-Term Care. He obtained his Pharmacy degree from Robert Gordon’s University in Aberdeen, Scotland, and holds an MBA from Warwick University in England.

Madhu Venkat

Madhu Venkat, a Canadian citizen, possesses over 25 years of CEO-level experience in the healthcare markets of North and South America. He serves as a significant stakeholder in LevoMed Canada, a successful healthcare company established in 2010. LevoMed holds the exclusive distribution rights for a unique medical device called AGM 100 in Canada. Additionally, LevoMed has substantial investments in LevoPharm, which operates in the retail pharmacy sector, and Ambicare Pharmaceuticals Inc., a Canadian startup pharma company having tie up with a large pharma group based in Asia.

In 2011, Madhu co-promoted Natco Canada and served as its CEO before choosing to retire in 2022. Natco Canada boasts a revenue of nearly $200 million and stands as the most profitable subsidiary of Natco Pharma Limited, India. By being the first to market and capturing significant market share, Madhu successfully launched various key generic Rx products in the Canadian market. He assembled a team of highly motivated professionals who continue to deliver substantial value to Natco.

Prior to his involvement with Natco Canada, Madhu held position of President and CEO at Cellofarma, a Brazilian subsidiary of Strides. From its inception, he played a crucial role in building two manufacturing plants in Brazil, introducing several key generic products as pioneers, and expanding the subsidiary to become one of the top 10 pharma companies in Brazil. Eventually, this business was sold to Aspen (the oral dosage part) and Mylan (the sterile part).